TEV-50717 (Деутетрабеназин, SD-809, АУСТЕДО)
Открытое, долгосрочное исследование безопасности, включающее двойной слепой, плацебо-контролируемый, рандомизированный период выведения препарата TEV-50717 (деутетрабеназин) для лечения синдрома Туретта у детей и подростков
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/505/2018-10-01/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 6–17 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 21 чел. в стране «Россия».
- Центров в реестре: 3 в 3 городах. Список — ниже на странице.
- Плановая дата окончания (03.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 17
Критерии включения
- Patient is younger than 18 years of age on day 1
- Patient weighs at least 44 pounds (20 kg)
- The patient's active tics are causing distress or impairment
- Patient is able to swallow study medication whole
- Patient is in good general health
- Women/girls of childbearing potential whose male partners are of childbearing potential must use contraception for the duration of the study -- Additional criteria apply, please contact the investigator for more information
Критерии невключения
- Patient is 18 years of age or older.
- Patient has a neurologic disorder other than TS that could obscure the evaluation of tics.
- The patient's predominant movement disorder is stereotypy (coordinated movements that repeat continually and identically) associated with autism spectrum disorder.
- Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder.
- Patient has clinically significant depression at screening or day 1. Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose for at least 6 weeks before screening.
- Patient has a history of suicidal intent or related behaviors within 2 years of screening
- Patient has a history of a previous actual, interrupted, or aborted suicide attempt.
- Patient has a first-degree relative who has completed suicide.
- Patient has clinically significant obsessive-compulsive disorder (OCD) on day 1 that, in the opinion of the investigator, is the primary cause of impairment.
- Patient has received comprehensive behavioral intervention for tics for TS or cognitive behavioral therapy for OCD within 4 weeks of screening.
- Patient has received treatment with deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation for reduction of tics within 4 weeks of the screening visit.
- Patient has an unstable or serious medical illness at screening or day 1
- Patients with a history of torsade de pointes, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure.
- Patient has received a monoamine oxidase inhibitor within 14 days of the day 1 visit.
- Patient has participated in an investigational drug or device study (with the exception of Study SD-809-C-17, Study TV50717-CNS-30046, or Study TV50717-CNS-30060) and received IMP/intervention within 30 days or 5 drug half-lives of day 1, whichever is longer.
- The patient is a pregnant or lactating female, or plans to become pregnant during the study.
- Patient has a history of, or acknowledges, alcohol-related disorder in the previous 12 months -- Additional criteria apply, please contact the investigator for more information
Источник: ClinicalTrials.gov, NCT03567291 · запись обновлена в реестре 9 ноября 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (8), вторичных — 5
- Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B Combined — Day 1 to Week 55
- Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II) — Weeks 28 to 30
- Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score — Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
- Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score — Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
- Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score at Week 30 — Week 28, Week 30
- Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score at Week 30 — Week 28, Week 30
- Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS) — Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
- Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS) at Randomized Withdrawal Baseline Visit (Week 28) and Week 30 — Week 28, Week 30
Цель исследования
This is an otherwise open-label, single-arm study that includes a 2-week, double-blind, placebo controlled, randomized drug withdrawal period followed by a 3 week blinded maintenance or re-titration, and then a maintenance period. This study aims to evaluate the safety and efficacy of TEV-50717 tablets in patients with tics associated with TS who have previously completed participation in any of the parent studies.
Области и заболевания
Где проходит
3 центра в 3 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 505 от 01.10.2018 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик, центры
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03567291 Официальный реестр (США) · загружено 9 ноября 2026Цель
-
clinmarket · № 1422 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.